Antibiotic shows promise against Lyme disease at a fraction of the dosage
A Northwestern University study reveals that piperacillin, a common antibiotic, effectively treats Lyme disease in mice at a much lower dose than doxycycline, the current standard. This reduced dosage minimizes harm to beneficial gut bacteria, a significant drawback of existing treatments. Piperacillin, already FDA-approved, could also potentially serve as a preventive measure against Lyme disease following tick bites.
Lyme disease
affects nearly half a million individuals in the United States annually. The disease caused by the bacterium
Borrelia burgdorferi
and rarely, Borrelia mayonii is spread to humans through the bite of infected blacklegged ticks, known as deer ticks. Lyme disease can be devastating even in acute cases, so early treatment with
antibiotics
is crucial to prevent chronic symptoms like heart and neurological problems and arthritis.
Scientists from Northwestern University have found that a specific antibiotic can cure Lyme disease effectively, and only requires 1/100th of the dose of the treatment currently being used. The study published in the journal Science Translational Medicine revealed that piperacillin, an antibiotic in the same class as penicillin, effectively Lyme disease in mice at 100 times less than the dose of doxycycline, the current gold standard treatment. The study revealed that at such a low dose,
piperacillin
also had the added benefit of 'having virtually no impact on resident gut microbes.'
Though doxycycline and other generic antibiotics treat the disease, they wreak havoc on the microbiome by killing the beneficial gut bacteria. Doxycycline also fails in 10 and 20% of individuals who take it, and it is not approved for use in young children, who are especially at the highest risk of tick bites, resulting in Lyme.
'Powerful, broad-spectrum antibiotics that kill extracellular bacteria are seen as the most effective medication because physicians want to just kill the bacterium and don't care how. This is certainly a reasonable approach, but I think the future for Lyme disease patients is bright in that we are approaching an era of customized medicine, and we can potentially create a particular drug, or a combination to treat Lyme disease when others fail. The more we understand about the various strains and species of Lyme disease-causing Borrelia, the closer we get to a custom approach,' Brandon L. Jutras, who led the research, and ios an associate professor in the microbiology-immunology department of Northwestern University Feinberg School of Medicine, and a member of Northwestern's Center for Human Immunobiology, said in a statement.
Trump Demands This From China Amid Tariff War... | 'U.S. No Longer Lose On Trade'
The researchers stated that the piperacillin, which has already been FDA-approved as a safe treatment for pneumonia, could also be used as a preventive treatment. If someone is bitten by a deer tick and might have been exposed to Lyme disease, they could get a one-time shot of the medication to help prevent infection.
The study said that penicillin is relatively the most effective and targeted treatment. Piperacillin is usually given with another drug, tazobactam, to treat serious strep infections. This is because strep can block piperacillin from working unless tazobactam is there to stop the enzyme that breaks it down. Jutras also looked at the option of using both drugs together as they might work better than using piperacillin alone.
'Bacteria are clever. Strep and some other bacteria combat antibiotics by secreting beta-lactamases that inactivate piperacillin. We found the approach is totally irrelevant in the context of Lyme disease, and another way that makes piperacillin more specific. Adding the beta-lactamase inhibitor doesn't improve the therapy because Lyme Borrelia don't produce beta-lactamase, but the cocktail does negatively impact the microbiome by becoming more broadly functional against beneficial residents,' Jutras added.
Curbing Lyme disease is a challenge, given that there are no approved human vaccines as of now, and this new research could be a way forward.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
an hour ago
- Hans India
Alzheimer's gene therapy shows promise to prevent brain damage
New Delhi: A novel gene therapy for Alzheimer's disease, which showed promise to protect the brain from damage and preserve cognitive function, has renewed hope for millions of patients with the neurodegenerative disease. Worldwide, approximately 57 million people live with dementia, and Alzheimer's disease is the most common cause, accounting for 60-70 per cent of cases. Alzheimer's occurs when abnormal proteins build up in the brain, leading to the death of brain cells and declines in cognitive function and memory. While current treatments can manage symptoms of Alzheimer's, the new gene therapy aims to halt or even reverse disease progression, said researchers from the University of California San Diego School of Medicine. They noted that, unlike existing treatments for Alzheimer's that target unhealthy protein deposits in the brain, the new approach could help address the root cause of Alzheimer's disease by influencing the behaviour of brain cells themselves. The study investigated the effect of hippocampal SynCav1 delivery in two distinct preclinical mice models. The results, published in the journal Signal Transduction and Targeted Therapy, showed that delivering the treatment at the symptomatic stage of the disease preserved hippocampal-dependent memory -- a critical aspect of cognitive function that is often impaired in Alzheimer's patients. Further, the finding stated that compared to healthy mice of the same age, the treated mice also had a similar pattern of gene expression. This suggests that the treatment has the potential to alter the behaviour of diseased cells to restore them to a healthier state. 'While multiple newly FDA-approved treatments focus on targeting amyloid-beta clearance in Alzheimer's patients, the therapeutic value of SynCav1 lies in its ability to protect vulnerable neurons and augment cellular responses -- mechanisms that differ from currently approved therapies,' said the researchers in the paper. Due to the multitude of neurotoxicity in the Alzheimer's brain, the team called for further studies to investigate SynCav1's therapeutic role when combined with amyloid-targeted drugs to enhance clinical outcomes.
NDTV
2 hours ago
- NDTV
Deport "Illegal Alien" Elon Musk: Ex Aide's Advice To Donald Trump
Hours after a public fallout between Elon Musk and Donald Trump, a former close aide of the US President questioned the immigration status of the Tesla CEO. Steve Bannon, a former White House strategist, called Musk "an illegal alien" who should be deported. He also urged the US government to seize the tech billionaire's company, SpaceX. Speaking with The New York Times, Bannon, one of Musk's most vocal critics, said, "They [US government] should initiate a formal investigation of his immigration status because I am of the strong belief that he is an illegal alien, and he should be deported from the country immediately." His statement came after Musk threatened to shut down SpaceX's Dragon spacecraft that carries astronauts to and from the International Space Station (ISS). Bannon argued this could be a serious threat to the country, so Trump should sign an order under the Defense Production Act to take over SpaceX immediately. The Defense Production Act, a law from the time of the Korean War, gives the President the power to mandate private businesses to prioritise and accept government contracts for certain products such as weapons and medical supplies. On his podcast "War Room," Bannon said, "The action that President Trump should be taking immediately, I think, is when [Musk] threatens to take one of the big programs out of Space X, President Trump tonight should sign an executive order calling for the Defense Production Act to be called in on SpaceX and seize SpaceX tonight, before midnight." He didn't stop there. The former executive chairman of the right-wing Breitbart News website urged the US government to look into Musk's alleged drug use. He alleged the Tesla CEO tried to get secret information from the Pentagon about China. He further asked the Trump administration to put Musk's security clearance on hold and cancel all contracts with his companies. On Thursday, tensions peaked between Musk and Trump escalated after the billionaire's criticism of Trump's "One Big Beautiful Bill." Trump responded, saying he once had a good relationship with Musk, but now he was unsure if it would continue the same way. Musk fired back, accusing the Trump administration of withholding records related to Jeffrey Epstein, claiming the President's name was there.
Hindustan Times
3 hours ago
- Hindustan Times
Contraceptives for poorest countries stuck in warehouses after US aid cuts
* Stock includes condoms, implants, pills and IUDs * Options include selling, donating or destroying stock * US State Department says no decision yet on next move LONDON, - Contraceptives that could help prevent millions of unwanted pregnancies in some of the world's poorest countries are stuck in warehouses because of U.S. aid cuts and could be destroyed, two aid industry sources and one former government official said. The stock, held in Belgium and Dubai, includes condoms, contraceptive implants, pills and intrauterine devices, together worth around $11 million, the sources told Reuters. It has been stalled since the Trump administration started cutting foreign aid as part of its 'America First' policy in February, as the U.S. government no longer wants to donate the contraceptives or pay the costs for delivery, they said. The U.S. Agency for International Development has instead asked the contractor managing its health supply chain, Chemonics, to try to sell it, two of the sources said. An internal USAID memo, sent in April, said a quantity of contraceptives was being kept in warehouses and they should be "immediately transferred to another entity to prevent waste or additional costs". A senior U.S. State Department official told Reuters no decision had been made about the future of the contraceptives. They did not respond to questions about the reasons why the contraceptives were in storage or the impact of the U.S. aid cuts and delays. A spokesperson for Chemonics said they were unable to comment on USAID's plans, but added that the company is working with clients to deliver life-saving aid globally and would continue to support the U.S. government's global health supply chain priorities. The stock represents just under 20% of the supply of contraceptives bought annually by the U.S. for donation overseas, a former USAID official told Reuters. Selling or donating the contraceptives has been challenging, according to the former USAID official, although talks are ongoing. Another option on the table is destroying it, at a cost of several hundred thousand dollars. As time goes on, shelf-lives will also become an issue, one of the sources said. The sources told Reuters that one of the key delays is a lack of response from the U.S. government about what should be done with the stock. It had been destined largely for vulnerable women in sub-Saharan Africa, including young girls who face higher health risks from early pregnancy as well as those fleeing conflict or who otherwise could not afford or access the contraceptives, the sources added. The condoms also help stop the spread of HIV, the former USAID official said. "We cannot dwell on an issue for too long; when urgency and clarity don't align, we have to move on," said Karen Hong, chief of UNFPA's supply chain. She said the agency is now working on Plan B to help fill critical supply gaps.
